In the context of antibody-based technologies, the m909 CAR T cell therapy has led to in vivo AML tumour regression, while in the field of nanotherapeutics, the FRβ-targeted liposome f-L-DOX has demonstrated the ability to induce cytotoxicity in FRβ-positive BAL cancer cells. The gene discussed is FOLR2; the disease is cancer.